SEER

Seer, Inc. Class A Common Stock (SEER) | Rumor.io

Seer

SEER

Attention (50-day avg)0%

Attention rank (50-day avg)#3,191

Bullish sentiment (50-day avg)0%

Price to earnings ratio-1.59

Market capitalization112.4M

Earnings per share-1.22

Dividend yield (TTM)—

Revenue (annual)16.1M

Net income (annual)-73.6M

Social

What share of all stock conversation is about SEER?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 6

Seer, Inc. ($SEER) CEO's $2.45/share buyout proposal with CVRs sparked a 25% premarket surge.
The proposal was met with resistance from the Radoff JeC group, who agreed that Seer should not be a public company and should be sold to the highest bidder.
Seer's stock price has been volatile, with a 37% surge to $2.22 on high volume, and some analysts believe a bidding war could begin.

Generated by AI

Sentiment

Of the messages about SEER that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.5% -11.18
Bearish	—	—	—	12.5% +11.18

Jul 6

$SEER has been identified as a potential takeover target, with a buyout proposal submitted by its CEO, which could lead to a higher stock price.
The stock has seen significant price appreciation, with a 37% increase on the session and a 30.9% pre-market gain, indicating strong investor interest.
The company's volume has been growing to the upside, suggesting a strong trend in the stock, and some analysts believe the stock could reach at least $2.45 based on the CEO's buyout offer.

Generated by AI

Topics

Of the messages about SEER that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	80.44%
Controversies	—	—	0%	4.44%
Analysts	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	15.11%

Mar 3

Seer, Inc. (SEER) is mentioned in multiple posts regarding a clinical study on Bentrio, a product developed by CytoDyn (CYTO), demonstrating superior nasal residence time and rheological properties.
The study's results are considered breaking news, indicating a significant development in the medical and pharmaceutical industries.
CytoDyn's (CYTO) product Bentrio is gaining attention for its potential benefits, which may have a positive impact on the company's stock price and the overall market.

Generated by AI

Community

Of the messages about SEER, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	3.45%
Newcomers	—	—	100%	96.55%

Mar 3

Newcomers are noticing a disconnect between $SEER's stock performance and its potential as an old-gen proteomics play, with some seeing it as a better value compared to newer players like Nautilus.
The parabolic SAR indicator has turned positive for $SEER, indicating a potential uptrend, and momentum is rising according to the chart.
Some users are getting excited about Seer, Inc.'s potential, possibly due to the company's involvement with Bentrio's clinical study results, which demonstrate superior nasal residence time and rheological properties.

Generated by AI

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to present on Wednesday, August 12th from 8:00 a.m. to 8:25 a.m. Eastern Time / 5:00 a.m. to 5:25 a.m. Pacific Time. A live webcast of the session will be available on the Investor

1mo agofinance.yahoo.com

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2026 on Tuesday, August 11, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archiv

1mo agoYahoo Finance

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

No Stockholder Action Required at This TimeREDWOOD CITY, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that on July 28, 2026, it received a further revised, unsolicited, non-binding acquisition proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) to acquire all of the outstanding shares of Seer’s Class A common stock for $2

2mo agouk.finance.yahoo.com

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer”) today announced that, based on the preliminary voting results from Seer’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), Seer stockholders have voted to re-elect all seven of Seer’s director nominees – Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D. – to Seer’s Board of Directors (the “Board”). Seer issue

2mo agoYahoo Finance

This Seer Vote Could Decide Between Takeout Optionality And Standalone Path (NASDAQ:SEER)

2mo agoSeeking Alpha

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors, consisting of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected the unsolicited, non-binding proposal received on July 1, 2026, from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire al

2mo agoYahoo Finance

Also Discussed

Investors talking about SEER also mention

#	Name	Attention
1	908 Devices Inc.MASS	0%0
2	Quanterix CorporationQTRX	0%new
3	Quantum-Si Incorporated Class A Common StockQSI	0.02%+0.02
4	Nautilus Biotechnology, Inc.NAUT	0%-0.15
5	10x Genomics Inc. Class A Common StockTXG	0%-0.02
6	Twist Bioscience CorporationTWST	0%-0.02
7	KZR - Kezar Life Sciences, Inc.	——
8	OLK - Olink Holding AB (publ)	——
9	Codexis Inc.CDXS	0%0
10	Pacific Biosciences of California, Inc. Common StockPACB	0%0

Seer, Inc. Class A Common Stock

Healthcare
Biotechnology

Seer, Inc. Class A Common Stock represents ownership in Seer, a life sciences company focused on proteomics. Seer develops and commercializes the Proteograph Product Suite, an integrated platform that combines proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to support high-throughput protein analysis. Its products are designed for research use in academic institutions, biotechnology and biopharmaceutical companies, and other scientific laboratories seeking deeper, more unbiased insights into biological samples. By enabling protein profiling at scale, Seer plays a specialized role in the broader tools-and-services segment of the life sciences market, where proteomic technologies support biomarker discovery, drug research, and translational science. The company is headquartered in Redwood City, California.

Website

Location

3800 Bridge Parkway

Redwood City, CA, 94065

United States

Social

What share of all stock conversation is about SEER?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 6

Seer, Inc. ($SEER) CEO's $2.45/share buyout proposal with CVRs sparked a 25% premarket surge.
The proposal was met with resistance from the Radoff JeC group, who agreed that Seer should not be a public company and should be sold to the highest bidder.
Seer's stock price has been volatile, with a 37% surge to $2.22 on high volume, and some analysts believe a bidding war could begin.

Generated by AI

Sentiment

Of the messages about SEER that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.5% -11.18
Bearish	—	—	—	12.5% +11.18

Jul 6

$SEER has been identified as a potential takeover target, with a buyout proposal submitted by its CEO, which could lead to a higher stock price.
The stock has seen significant price appreciation, with a 37% increase on the session and a 30.9% pre-market gain, indicating strong investor interest.
The company's volume has been growing to the upside, suggesting a strong trend in the stock, and some analysts believe the stock could reach at least $2.45 based on the CEO's buyout offer.

Generated by AI

Topics

Of the messages about SEER that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	80.44%
Controversies	—	—	0%	4.44%
Analysts	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	15.11%

Mar 3

Seer, Inc. (SEER) is mentioned in multiple posts regarding a clinical study on Bentrio, a product developed by CytoDyn (CYTO), demonstrating superior nasal residence time and rheological properties.
The study's results are considered breaking news, indicating a significant development in the medical and pharmaceutical industries.
CytoDyn's (CYTO) product Bentrio is gaining attention for its potential benefits, which may have a positive impact on the company's stock price and the overall market.

Generated by AI

Community

Of the messages about SEER, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	3.45%
Newcomers	—	—	100%	96.55%

Mar 3

Newcomers are noticing a disconnect between $SEER's stock performance and its potential as an old-gen proteomics play, with some seeing it as a better value compared to newer players like Nautilus.
The parabolic SAR indicator has turned positive for $SEER, indicating a potential uptrend, and momentum is rising according to the chart.
Some users are getting excited about Seer, Inc.'s potential, possibly due to the company's involvement with Bentrio's clinical study results, which demonstrate superior nasal residence time and rheological properties.

Generated by AI

Seer

Social

Jul 6

Sentiment

Jul 6

Topics

Mar 3

Community

Mar 3

News

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

This Seer Vote Could Decide Between Takeout Optionality And Standalone Path (NASDAQ:SEER)

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Also Discussed

Seer, Inc. Class A Common Stock

Company Information

Location

News

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

Seer to Report Second Quarter 2026 Financial Results on August 11, 2026

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.

Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

This Seer Vote Could Decide Between Takeout Optionality And Standalone Path (NASDAQ:SEER)

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Also Discussed

Social

Jul 6

Sentiment

Jul 6

Topics

Mar 3

Community

Mar 3